Fulgent Genetics, Inc. (NASDAQ:FLGT) CEO Sells $40,665.02 in Stock

Fulgent Genetics, Inc. (NASDAQ:FLGT) CEO Ming Hsieh sold 2,227 shares of the firm’s stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $18.26, for a total transaction of $40,665.02. Following the sale, the chief executive officer now owns 703,711 shares of the company’s stock, valued at approximately $12,849,762.86. The trade was a 0.32 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Fulgent Genetics Price Performance

Shares of FLGT traded up $0.18 during trading on Wednesday, reaching $18.07. 155,004 shares of the company traded hands, compared to its average volume of 185,564. Fulgent Genetics, Inc. has a twelve month low of $16.56 and a twelve month high of $30.68. The stock has a 50-day simple moving average of $20.05 and a 200-day simple moving average of $21.18.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. boosted its stake in shares of Fulgent Genetics by 0.6% in the first quarter. Vanguard Group Inc. now owns 1,424,448 shares of the company’s stock valued at $30,911,000 after purchasing an additional 8,257 shares during the period. Millennium Management LLC boosted its stake in shares of Fulgent Genetics by 34.3% in the second quarter. Millennium Management LLC now owns 958,852 shares of the company’s stock valued at $18,813,000 after purchasing an additional 244,981 shares during the period. State Street Corp boosted its stake in shares of Fulgent Genetics by 1.4% in the third quarter. State Street Corp now owns 793,545 shares of the company’s stock valued at $17,244,000 after purchasing an additional 10,868 shares during the period. Divisadero Street Capital Management LP boosted its stake in shares of Fulgent Genetics by 46.4% in the second quarter. Divisadero Street Capital Management LP now owns 505,212 shares of the company’s stock valued at $9,912,000 after purchasing an additional 160,212 shares during the period. Finally, Geode Capital Management LLC boosted its stake in shares of Fulgent Genetics by 2.7% in the third quarter. Geode Capital Management LLC now owns 502,869 shares of the company’s stock valued at $10,930,000 after purchasing an additional 13,320 shares during the period. Hedge funds and other institutional investors own 48.06% of the company’s stock.

Analyst Ratings Changes

Several research firms recently issued reports on FLGT. StockNews.com cut shares of Fulgent Genetics from a “hold” rating to a “sell” rating in a research report on Wednesday. Piper Sandler cut their price objective on shares of Fulgent Genetics from $26.00 to $22.00 and set a “neutral” rating for the company in a research report on Monday, November 11th.

About Fulgent Genetics

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.